List of works - Sandrine Faivre

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers

scientific article published on 01 October 2017

A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors

scientific article

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

scientific article

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

scientific article

A risk-benefit assessment of amifostine in cytoprotection

scientific article

Activity of oxaliplatin against human tumor colony-forming units.

scientific article

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.

scientific article published on 25 November 2016

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

scientific article published on 20 March 2014

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

scientific article

Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer

scientific article

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.

scientific article published on August 2010

Benzofuran derivatives as a novel class of inhibitors of mTOR signaling

scientific article published on 2 January 2014

Benzofuran derivatives as anticancer inhibitors of mTOR signaling

scientific article published on 5 May 2014

Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma.

scientific article

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

scientific article

Cancer wars: natural products strike back

scientific article

Cellular and molecular pharmacology of oxaliplatin.

scientific article

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

scientific article published on 29 April 2011

Cholangiocarcinoma: epidemiology and global management

scientific article

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

scientific article

Colorectal liver metastases growth in the embolized and non-embolized liver after portal vein embolization: influence of initial response to induction chemotherapy

scientific article published on 18 April 2014

Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.

scientific article published on 11 January 2011

Could we expect to improve survival in small cell lung cancer?

scientific article published on August 2007

Current development of mTOR inhibitors as anticancer agents

scientific article

Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.

scientific article published on 24 September 2013

Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy

scientific article

Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction

scientific article published in November 2002

Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors

scientific article

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.

scientific article

Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas.

scientific article

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma

scientific article published on 25 November 2014

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. ⬇️

scientific article published in April 2008

Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.

scientific article published on 22 June 2016

End points for new agents in induction chemotherapy for locally advanced head and neck cancers.

scientific article

Epidermal growth factor inhibitors

scientific article

Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma

scientific article published on 2 December 2010

Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells

scientific article published on 20 April 2010

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

scientific article published on May 2016

Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma.

scientific article published on 06 March 2013

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies

scientific article

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

scientific article

Hyperselective intra-arterial preoperative chemotherapy in patients with squamous cell carcinoma of the oral cavity: preliminary results

scientific article published in October 2006

Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.

scientific article

Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands

scientific article published in September 2005

Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -inde

scientific article published on August 2005

Induction chemotherapy challenges for head and neck cancer

scientific article published on 13 February 2013

Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis

scientific article

Irinotécan et dysfonctions hépatiques

scientific article published on 01 March 2007

Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours

scientific article published on December 2014

Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

scientific article published on 21 March 2016

Lessons learned in the development of targeted therapy for malignant gliomas.

scientific article published on July 2007

Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.

scientific article

Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck

scientific article

Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma

scientific article published on 01 April 1997

MEK in cancer and cancer therapy

scientific article published on 09 October 2013

Management of neuromuscular dose limiting toxicity at the early stage of drug development

article

Mechanism of action of rapalogues: the antiangiogenic hypothesis

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

scientific article

Methods for adjusting for bias due to crossover in oncology trials.

scientific article published in June 2014

Molecular basis for sunitinib efficacy and future clinical development

scientific article published on September 2007

Molecular detection of early-stage laryngopharyngeal squamous cell carcinomas

scientific article

Molecular mechanisms of apoptosis regulation

scientific article published on 01 September 1998

Neither preoperative computed tomography nor intra-operative examination can predict metastatic lymph node in the hepatic pedicle in patients with colorectal liver metastasis.

scientific article published on 12 August 2011

New drugs in bronchial cancer

scientific article published in May 2002

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

scientific article published on August 2010

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

scientific article published on August 2006

New treatment options with cytotoxic agents in neuroendocrine tumours.

scientific article published on 22 August 2012

Novel Anticancer Agents in Clinical Trials for Well-Differentiated Neuroendocrine Tumors ⬇️

scientific article published on December 1, 2010

Novel TGF-β inhibitors ready for prime time in onco-immunology

scientific article published on 7 December 2016

Novel molecular therapies in hepatocellular carcinoma.

scientific article published on January 2011

Optimal management of nasopharyngeal carcinoma.

scientific article published on May 2004

Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

scientific article published on 01 September 1999

Oxaliplatin in colorectal cancer: an overview.

scientific article

Oxaliplatin: mechanism of action and antineoplastic activity

scientific article published on 01 April 1998

PD-020Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib

scientific article published on 21 June 2016

Paclitaxel (Taxol?? )-associated junctional tachycardia ⬇️

scientific article published on August 1, 1997

Pancreatic NETs: where do we stand now?

scientific article published on March 2014

Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.

scientific article

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas

scientific article published on January 2014

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

scientific article published in August 2005

Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study

scientific article

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

scientific article

Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.

scientific article published on 19 September 2005

Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

scientific article

Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients

scientific article

Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.

scientific article published on December 2000

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

scientific article published on 16 September 2015

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies

scientific article

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

scientific article published on 6 September 2010

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

scientific article published on 25 October 2011

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

scientific article published in February 2004

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies

scientific article

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma

scientific article

Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

article

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

scientific article published on 16 November 2009

Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.

scientific article published on 16 September 2014

Preclinical and clinical development of novel agents that target the protein kinase C family

scientific article published on August 2006

Preclinical studies of oxaliplatin in combination chemotherapy

scientific article published in August 2001

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound

scientific article published on 20 March 2013

Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab

scientific article

Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck

scientific article published in April 2005

Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue

scientific article published on 07 July 2012

Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection

scientific article published on 13 March 2012

Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation

scientific article

Reappraisal of the Risks and Benefits of Major Liver Resection in Patients With Initially Unresectable Colorectal Liver Metastases

scientific article published on 01 November 2012

Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma

scientific article

Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma

scientific article published in April 2010

RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion.

scientific article published on April 2002

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

scientific article

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

scientific article

Safety of Liver Resection for Hepatocellular Carcinoma After Sorafenib Therapy: A Multicenter Case-Matched Study

scientific article published on 29 May 2013

Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies

scientific article published on 4 March 2008

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

scientific article

Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells

scientific article

Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis

scientific article published on November 2016

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

scientific article published in August 2005

Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study

scientific article published on 10 November 2016

Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential

scientific article

Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.

scientific article published on 9 November 2009

Sunitinib in pancreatic neuroendocrine tumors.

scientific article published on 02 June 2012

Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

scientific article

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

scientific article published on January 1999

Surgical Results after Downstaging of Initially Marginal or Non-Resectable Liver Metastases

scientific article published on 23 November 2012

Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes.

scientific article published on 13 February 2013

Targeted therapies and their indications in solid neoplasias

scientific article

Targeted therapies in hepatocellular carcinoma

scientific article published on 7 April 2010

Targeting cancer cell metabolism in pancreatic adenocarcinoma

scientific article published on July 2015

Targeting neuroendocrine tumor: mixing standard options with novel therapies

scientific article published on 24 August 2012

Targeting the TGFβ pathway for cancer therapy.

scientific article

Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.

scientific article

The role of integrins in colorectal cancer.

scientific article published on August 2007

Topics in mTOR pathway and its inhibitors

scientific article published in January 2009

Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.

scientific article

Tyrosine kinase inhibition and grey hair

scientific article published in March 2003

Understanding c-MET signalling in squamous cell carcinoma of the head & neck

scientific article published on 12 January 2017

[Advanced hepatocellular carcinoma: importance of clinical trials].

scientific article published in May 2015

[Basaloid squamous cell carcinomas of the head and neck]

scientific article published on 01 October 2009

[Epidermoid carcinoma of the head and neck: contribution of chemotherapy in case of recurrence and locally advanced disease. Review of the literature]

scientific article published on 01 December 2000

[Gemcitabine and pemetrexed: novel associations and mechanisms of resistance]

scientific article published on 01 January 2007

[Inhibition of telomeres and telomerase. Seeking for new anticancer drugs]

scientific article

[Molecular mechanism in the regulation of apoptosis]

scientific article published on 01 September 1998

[Non-AIDS-related malignancies: prognostic and treatment]

scientific article published on 01 May 2003

[PI3K-AKT-mTOR pathway and cancer]

scientific article published on 01 February 2012

[Phase I cancer trials methodology]

scientific article published on 01 November 2007

[Prognosis factors of cholangiocarcinoma: contribution of recent molecular biology tools].

scientific article published in April 2009

[Targeted therapies in colorectal cancer]

scientific article published on 01 October 2010

[Targeted therapies in hepatocellular carcinomas: recent results and future development]

scientific article published on 01 May 2009

[Zd 1839 "Iressa"]

scientific article published on 01 December 2000

c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside.

scientific article

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

scientific article published on 16 September 2008

List of works by Sandrine Faivre

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers

A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

A risk-benefit assessment of amifostine in cytoprotection

Activity of oxaliplatin against human tumor colony-forming units.

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.

Benzofuran derivatives as a novel class of inhibitors of mTOR signaling

Benzofuran derivatives as anticancer inhibitors of mTOR signaling

Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma.

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial

Cancer wars: natural products strike back

Cellular and molecular pharmacology of oxaliplatin.

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

Cholangiocarcinoma: epidemiology and global management

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Colorectal liver metastases growth in the embolized and non-embolized liver after portal vein embolization: influence of initial response to induction chemotherapy

Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.

Could we expect to improve survival in small cell lung cancer?

Current development of mTOR inhibitors as anticancer agents

Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.

Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy

Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction

Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.

Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas.

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. ⬇️

Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.

End points for new agents in induction chemotherapy for locally advanced head and neck cancers.

Epidermal growth factor inhibitors

Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma

Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma.

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Hyperselective intra-arterial preoperative chemotherapy in patients with squamous cell carcinoma of the oral cavity: preliminary results

Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.

Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands

Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -inde

Induction chemotherapy challenges for head and neck cancer

Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis

Irinotécan et dysfonctions hépatiques

Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours

Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

Lessons learned in the development of targeted therapy for malignant gliomas.

Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.

Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck

Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma

MEK in cancer and cancer therapy

Management of neuromuscular dose limiting toxicity at the early stage of drug development

Mechanism of action of rapalogues: the antiangiogenic hypothesis

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

Methods for adjusting for bias due to crossover in oncology trials.

Molecular basis for sunitinib efficacy and future clinical development

Molecular detection of early-stage laryngopharyngeal squamous cell carcinomas

Molecular mechanisms of apoptosis regulation

Neither preoperative computed tomography nor intra-operative examination can predict metastatic lymph node in the hepatic pedicle in patients with colorectal liver metastasis.

New drugs in bronchial cancer

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

New treatment options with cytotoxic agents in neuroendocrine tumours.

Novel Anticancer Agents in Clinical Trials for Well-Differentiated Neuroendocrine Tumors ⬇️

Novel TGF-β inhibitors ready for prime time in onco-immunology

Novel molecular therapies in hepatocellular carcinoma.

Optimal management of nasopharyngeal carcinoma.

Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

Oxaliplatin in colorectal cancer: an overview.

Oxaliplatin: mechanism of action and antineoplastic activity

PD-020Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Paclitaxel (Taxol?? )-associated junctional tachycardia ⬇️

Pancreatic NETs: where do we stand now?

Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas